Breaking News, Collaborations & Alliances

BioMoti Partners with Pharma Company to Develop Ovarian Cancer Treatment

Dr. John Beadle joins Board of Directors as chairman.

Author Image

By: Charlie Sternberg

Associate Editor

BioMoti Ltd has signed an agreement with a global pharmaceutical company to collaborate on the development of its lead ovarian cancer candidate, BMT101, to clinical phase 2a proof-of-concept.   The collaboration agreement provides access to the partner company’s expertise including its proprietary commercial manufacturing technology and an option for the global pharmaceutical company to license BMT101 in specific territories.   BMT101, BioMoti’s lead candidate for the unmet need in ovarian c...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters